logo
  • 首页
  • 学术期刊
  • 论文检测
  • AIGC检测
  • 热点
  • 更多
    • 数据

Bevacizumab/steroids/thalidomideLack of efficacy and off label use: case report

被引:0
|
作者:
机构:
来源:
Reactions Weekly | 2022年 / 1933卷 / 1期
关键词:
D O I:
10.1007/s40278-022-28071-4
中图分类号:
学科分类号:
摘要:
引用
收藏
页码:120 / 120
相关论文
共 50 条
  • [21] AntineoplasticsLack of efficacy and off label use: case report
    Reactions Weekly, 2024, 2021 (1) : 60 - 60
  • [22] AntineoplasticsLack of efficacy and off label use: case report
    Reactions Weekly, 2023, 1938 (1) : 144 - 144
  • [23] Aflibercept/bevacizumab/metoprololTreatment failure and off label use: case report
    Reactions Weekly, 2022, 1924 (1) : 29 - 29
  • [24] BevacizumabAnosmia and ageusia following off label use of bevacizumab: case report
    Reactions Weekly, 2019, 1753 (1) : 74 - 74
  • [25] Steroids/tocilizumabLack of efficacy during off-label therapy: case report
    Reactions Weekly, 2022, 1925 (1) : 459 - 459
  • [26] Mesalazine/thalidomideLack of efficacy: case report
    Reactions Weekly, 2021, 1853 (1) : 291 - 291
  • [27] Adalimumab/thalidomideLack of efficacy: case report
    Reactions Weekly, 2022, 1894 (1) : 21 - 21
  • [28] Cobimetinib/thalidomideLack of efficacy: case report
    Reactions Weekly, 2023, 1939 (1) : 150 - 150
  • [29] Dexamethasone/thalidomideLack of efficacy: case report
    Reactions Weekly, 2024, 2030 (1) : 164 - 164
  • [30] Avapritinib/ImatinibLack of efficacy and off label use: case report
    Reactions Weekly, 2024, 2037 (1) : 71 - 71
← 12345 →